

CSD/BSE&NSE/2023-24
September 26, 2023

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015

.....

We are pleased to inform you that the Company has received an intimation on September 25, 2023, that the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has granted its approval for acquisition of up to 76.1% shareholding in the Company by M/s. Berhyanda Limited, Cyprus (“**Acquirer**”) by way of transfer of 12,75,37,043 equity shares aggregating to 50.1% of shareholding in the Company from promoters of the Company (M/s Jasti Property and Equity Holdings Private Limited) and acquisition of up to 6,61,86,889 equity shares aggregating to 26% of shareholding in the Company from public shareholders through mandatory open offer. The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the Company.

The Acquirer will hold 76.1% of the paid-up share capital of the Company and other foreign investors including FPIs will hold up to 14% of paid-up share capital of the Company subject to compliance with the regulations under various laws and the terms and conditions as specified in the letter of approval.

This is for your information and records.

Thanking you,
Yours faithfully,
For Suven Pharmaceuticals Limited

K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited